XBiotech Inc.

NASDAQ:XBIT

Biotechnology

Healthcare
$1.68 -0.84%

-$0.02 today

Market cap
$51.22M
Beta
0.84
P/E (TTM)
-1.8
EPS (TTM)
-$1.32
52W Low $2.09High $3.61

Volume 0.05M

Average 0.03M

Returns on capital

XBiotech Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-32.4%

avg -21.1%

ROIC

-39.2%

avg -30.9%

ROA

-30.3%

avg -19.5%

Analysis

ROA is currently the strongest return metric at -30.3% versus its period average of -19.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

John Simard

Founder & ChairmanUSD 27.13M644.26M13.98%

Sushma Shivaswamy

Co-CEO & Chief Scientific OfficerUSD 570.99K48100.00K0.33%

Angela Hu

Director of FinanceUSD 245.42K4230.00K0.10%

Qian Wu

Senior Vice President of Clinical Operations & Analytical Quality————

Jan-Paul Simard

Co-Chief Executive Officer—242.00M6.56%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 3, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

2

$854,660.32

Sells

0

$0.00

Net Transaction Value

+$854,660.32

Net buying

Most Active

SIMARD JOHN

2 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 3, 26

SIMARD JOHN

Direct

Buy$143.4K
Oct 26, 26

SIMARD JOHN

Direct

Buy$711.3K

Summary

Insiders reported 2 buys worth $854,660.32 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $854,660.32. SIMARD JOHN was the most active insider with 2 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A —
RevenueN/AN/AN/A
N/A —
Net IncomeN/AN/AN/A
N/A —
EBITN/AN/AN/A
N/A —

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does XBiotech Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about XBIT's management, answered from reported figures.

Who manages XBIT?

XBiotech Inc. (XBIT) lists 5 active executives. The top listed executive is Qian Wu, Senior Vice President of Clinical Operations & Analytical Quality.

Are XBIT insiders buying or selling?

Recent insider activity shows net selling of $406.71M.